Financials in USD. Standardized financial statements.
A compact view of how POINT Biopharma Global Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $226.58M | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 |
| Gross Profit? | $226.58M | $0 | $0 | $0 |
| Gross Margin? | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $101.06M | $45.51M | $13.11M | $36,896 |
| Operating Income? | $125.52M | -$45.51M | -$13.11M | -$36,116 |
| EBITDA? | $127.32M | -$45.51M | -$13.11M | -$780 |
| Income Before Tax | $129.59M | -$45.60M | -$13.29M | -$36,896 |
| Income Tax Expense | $31.29M | $305,658 | $87,882 | $0 |
| Net Income? | $98.29M | -$45.90M | -$13.37M | -$36,896 |
| EPS? | $1.04 | $-0.62 | $-0.34 | $0.00 |
| Diluted EPS? | $1.02 | $-0.62 | $-0.34 | $0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality